Revamped Redx’s New CEO Says Porcupine Inhibitor Trials 'Now On Track'

 
• By Sten Stovall

After regulatory talks, revamped Redx gets green light to resume clinical study of RXC004 in patients with advanced solid tumors, while sister porcupine inhibitor RXC006 is set to enter IPF trials in 2020, the biotech's CEO tells Scrip.

Porcupine
REDX EXPLORING PORCUPINE INHIBITORS In Cancer, Lung Fibrosis • Source: Shutterstock

More from Clinical Trials

More from R&D